Trenstad is indicated in antiretroviral combination therapy for the treatment of HIV-1 and chronic hepatitis B infected adults aged 18 years and over.

Pack size Box of 30 tablets. Bottle of 60 tablets
Shelf-life 24 months
Composition Emtricitabine, Tenofovir disoproxil fumarate
Dosage forms and strengths Film-coated tablet:
Emtricitabine 200 mg
Tenofovir disoproxil fumarate 300 mg
Product code :



Treatment of HIV-1 and chronic hepatitis B infected adults aged 18 years and over.


Adults: 1 tablet once daily.

  • If a patient misses a dose within 12 hours, take one dose with food as soon as possible and resume their normal dosing schedule. If a patient misses a dose by more than 12 hours and it is almost time for the next dose, the patient should skip the missed dose and simply resume the usual dosing schedule.
  • If a patient vomits within 1 hour of taking Trenstad, another tablet should be taken. If a patient vomits more than 1 hour after taking Trenstad, do not need to take another dose.

Renal impairment:

  • Moderate renal impairment (creatinine clearance 30-49 ml/min): Take every 48 hours.
  • Severe renal impairment (creatinine clearance < 30 ml/min) and haemodialysis patients: Not recommended.


Trenstad is administered orally, once daily with food. If patients have difficulty in swallowing, can disintegrate one tablet in approximately 100 ml of water, orange juice or grape juice and take it immediately.

Known hypersensitivity to any ingredient in the formulation.

Very common

  • Headache, diarrhoea, nausea, elevated creatine kinase.
  • Hypophosphataemia, dizziness, vomiting, rash, asthenia.


  • Neutropenia, allergic reaction, hyperglycaemia, hypertriglyceridaemia.
  • Insomnia, abnormal dreams, dizziness, abdominal pain, dyspepsia.
  • Elevated pancreatic amylase, elevated serum lipase, elevated serum aspartate aminotransferase (AST) and/or elevated serum alanine aminotransferase (ALT), hyperbilirubinaemia.
  • Vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation), pain, asthenia.
  • Headache, abdominal pain, abdominal distension, flatulence, increased transaminases.
  • Adipogenic effects and opportunistic infections have been reported with antiretroviral therapy.
  • Trenstad should be avoided in antiretroviral experienced patients with HIV-1 harbouring the K65R mutation.
  • If there is evidence of worsening liver disease in patients with pre-existing liver dysfunction, interruption or discontinuation of treatment must be considered.
  • The use of Trenstad may be considered during pregnancy, if necessary. Trenstad should not be used during breast-feeding. As a general rule, HIV infected women do not breast-feed their infants in order to avoid transmission of HIV to the infant.
  • Patients should be aware of how they react to drug before driving or operating machinery.